Cargando…

Characteristic profiles of DNA epigenetic modifications in colon cancer and its predisposing conditions—benign adenomas and inflammatory bowel disease

BACKGROUND: Active demethylation of 5-methyl-2′-deoxycytidine (5-mdC) in DNA occurs by oxidation to 5-(hydroxymethyl)-2′-deoxycytidine (5-hmdC) and further oxidation to 5-formyl-2′-deoxycytidine (5-fdC) and 5-carboxy-2′-deoxycytidine (5-cadC), and is carried out by enzymes of the ten-eleven transloc...

Descripción completa

Detalles Bibliográficos
Autores principales: Dziaman, Tomasz, Gackowski, Daniel, Guz, Jolanta, Linowiecka, Kinga, Bodnar, Magdalena, Starczak, Marta, Zarakowska, Ewelina, Modrzejewska, Martyna, Szpila, Anna, Szpotan, Justyna, Gawronski, Maciej, Labejszo, Anna, Liebert, Ariel, Banaszkiewicz, Zbigniew, Klopocka, Maria, Foksinski, Marek, Marszalek, Andrzej, Olinski, Ryszard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5977551/
https://www.ncbi.nlm.nih.gov/pubmed/29875879
http://dx.doi.org/10.1186/s13148-018-0505-0
_version_ 1783327397993512960
author Dziaman, Tomasz
Gackowski, Daniel
Guz, Jolanta
Linowiecka, Kinga
Bodnar, Magdalena
Starczak, Marta
Zarakowska, Ewelina
Modrzejewska, Martyna
Szpila, Anna
Szpotan, Justyna
Gawronski, Maciej
Labejszo, Anna
Liebert, Ariel
Banaszkiewicz, Zbigniew
Klopocka, Maria
Foksinski, Marek
Marszalek, Andrzej
Olinski, Ryszard
author_facet Dziaman, Tomasz
Gackowski, Daniel
Guz, Jolanta
Linowiecka, Kinga
Bodnar, Magdalena
Starczak, Marta
Zarakowska, Ewelina
Modrzejewska, Martyna
Szpila, Anna
Szpotan, Justyna
Gawronski, Maciej
Labejszo, Anna
Liebert, Ariel
Banaszkiewicz, Zbigniew
Klopocka, Maria
Foksinski, Marek
Marszalek, Andrzej
Olinski, Ryszard
author_sort Dziaman, Tomasz
collection PubMed
description BACKGROUND: Active demethylation of 5-methyl-2′-deoxycytidine (5-mdC) in DNA occurs by oxidation to 5-(hydroxymethyl)-2′-deoxycytidine (5-hmdC) and further oxidation to 5-formyl-2′-deoxycytidine (5-fdC) and 5-carboxy-2′-deoxycytidine (5-cadC), and is carried out by enzymes of the ten-eleven translocation family (TETs 1, 2, 3). Decreased level of epigenetic DNA modifications in cancer tissue may be a consequence of reduced activity/expression of TET proteins. To determine the role of epigenetic DNA modifications in colon cancer development, we analyzed their levels in normal colon and various colonic pathologies. Moreover, we determined the expressions of TETs at mRNA and protein level. The study included material from patients with inflammatory bowel disease (IBD), benign polyps (AD), and colorectal cancer (CRC). The levels of epigenetic DNA modifications and 8-oxo-7,8-dihydro-2′-deoxyguanosine (8-oxodG) in examined tissues were determined by means of isotope-dilution automated online two-dimensional ultraperformance liquid chromatography with tandem mass spectrometry (2D-UPLC-MS/MS). The expressions of TET mRNA were measured with RT-qPCR, and the expressions of TET proteins were determined immunohistochemically. RESULTS: IBD was characterized by the highest level of 8-oxodG among all analyzed tissues, as well as by a decrease in 5-hmdC and 5-mdC levels (at a midrange between normal colon and CRC). AD had the lowest levels of 5-hmdC and 5-mdC of all examined tissues and showed an increase in 8-oxodG and 5-(hydroxymethyl)-2′-deoxyuridine (5-hmdU) levels. CRC was characterized by lower levels of 5-hmdC and 5-mdC, the lowest level of 5-fdC among all analyzed tissues, and relatively high content of 5-cadC. The expression of TET1 mRNA in CRC and AD was significantly weaker than in IBD and normal colon. Furthermore, CRC and AD showed significantly lower levels of TET2 and AID mRNA than normal colonic tissue. CONCLUSIONS: Our findings suggest that a complex relationship between aberrant pattern of DNA epigenetic modification and cancer development does not depend solely on the transcriptional status of TET proteins, but also on the characteristics of premalignant/malignant cells. This study showed for the first time that the examined colonic pathologies had their unique epigenetic marks, distinguishing them from each other, as well as from normal colonic tissue. A decrease in 5-fdC level may be a characteristic feature of largely undifferentiated cancer cells. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13148-018-0505-0) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5977551
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-59775512018-06-06 Characteristic profiles of DNA epigenetic modifications in colon cancer and its predisposing conditions—benign adenomas and inflammatory bowel disease Dziaman, Tomasz Gackowski, Daniel Guz, Jolanta Linowiecka, Kinga Bodnar, Magdalena Starczak, Marta Zarakowska, Ewelina Modrzejewska, Martyna Szpila, Anna Szpotan, Justyna Gawronski, Maciej Labejszo, Anna Liebert, Ariel Banaszkiewicz, Zbigniew Klopocka, Maria Foksinski, Marek Marszalek, Andrzej Olinski, Ryszard Clin Epigenetics Research BACKGROUND: Active demethylation of 5-methyl-2′-deoxycytidine (5-mdC) in DNA occurs by oxidation to 5-(hydroxymethyl)-2′-deoxycytidine (5-hmdC) and further oxidation to 5-formyl-2′-deoxycytidine (5-fdC) and 5-carboxy-2′-deoxycytidine (5-cadC), and is carried out by enzymes of the ten-eleven translocation family (TETs 1, 2, 3). Decreased level of epigenetic DNA modifications in cancer tissue may be a consequence of reduced activity/expression of TET proteins. To determine the role of epigenetic DNA modifications in colon cancer development, we analyzed their levels in normal colon and various colonic pathologies. Moreover, we determined the expressions of TETs at mRNA and protein level. The study included material from patients with inflammatory bowel disease (IBD), benign polyps (AD), and colorectal cancer (CRC). The levels of epigenetic DNA modifications and 8-oxo-7,8-dihydro-2′-deoxyguanosine (8-oxodG) in examined tissues were determined by means of isotope-dilution automated online two-dimensional ultraperformance liquid chromatography with tandem mass spectrometry (2D-UPLC-MS/MS). The expressions of TET mRNA were measured with RT-qPCR, and the expressions of TET proteins were determined immunohistochemically. RESULTS: IBD was characterized by the highest level of 8-oxodG among all analyzed tissues, as well as by a decrease in 5-hmdC and 5-mdC levels (at a midrange between normal colon and CRC). AD had the lowest levels of 5-hmdC and 5-mdC of all examined tissues and showed an increase in 8-oxodG and 5-(hydroxymethyl)-2′-deoxyuridine (5-hmdU) levels. CRC was characterized by lower levels of 5-hmdC and 5-mdC, the lowest level of 5-fdC among all analyzed tissues, and relatively high content of 5-cadC. The expression of TET1 mRNA in CRC and AD was significantly weaker than in IBD and normal colon. Furthermore, CRC and AD showed significantly lower levels of TET2 and AID mRNA than normal colonic tissue. CONCLUSIONS: Our findings suggest that a complex relationship between aberrant pattern of DNA epigenetic modification and cancer development does not depend solely on the transcriptional status of TET proteins, but also on the characteristics of premalignant/malignant cells. This study showed for the first time that the examined colonic pathologies had their unique epigenetic marks, distinguishing them from each other, as well as from normal colonic tissue. A decrease in 5-fdC level may be a characteristic feature of largely undifferentiated cancer cells. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13148-018-0505-0) contains supplementary material, which is available to authorized users. BioMed Central 2018-05-30 /pmc/articles/PMC5977551/ /pubmed/29875879 http://dx.doi.org/10.1186/s13148-018-0505-0 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Dziaman, Tomasz
Gackowski, Daniel
Guz, Jolanta
Linowiecka, Kinga
Bodnar, Magdalena
Starczak, Marta
Zarakowska, Ewelina
Modrzejewska, Martyna
Szpila, Anna
Szpotan, Justyna
Gawronski, Maciej
Labejszo, Anna
Liebert, Ariel
Banaszkiewicz, Zbigniew
Klopocka, Maria
Foksinski, Marek
Marszalek, Andrzej
Olinski, Ryszard
Characteristic profiles of DNA epigenetic modifications in colon cancer and its predisposing conditions—benign adenomas and inflammatory bowel disease
title Characteristic profiles of DNA epigenetic modifications in colon cancer and its predisposing conditions—benign adenomas and inflammatory bowel disease
title_full Characteristic profiles of DNA epigenetic modifications in colon cancer and its predisposing conditions—benign adenomas and inflammatory bowel disease
title_fullStr Characteristic profiles of DNA epigenetic modifications in colon cancer and its predisposing conditions—benign adenomas and inflammatory bowel disease
title_full_unstemmed Characteristic profiles of DNA epigenetic modifications in colon cancer and its predisposing conditions—benign adenomas and inflammatory bowel disease
title_short Characteristic profiles of DNA epigenetic modifications in colon cancer and its predisposing conditions—benign adenomas and inflammatory bowel disease
title_sort characteristic profiles of dna epigenetic modifications in colon cancer and its predisposing conditions—benign adenomas and inflammatory bowel disease
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5977551/
https://www.ncbi.nlm.nih.gov/pubmed/29875879
http://dx.doi.org/10.1186/s13148-018-0505-0
work_keys_str_mv AT dziamantomasz characteristicprofilesofdnaepigeneticmodificationsincoloncanceranditspredisposingconditionsbenignadenomasandinflammatoryboweldisease
AT gackowskidaniel characteristicprofilesofdnaepigeneticmodificationsincoloncanceranditspredisposingconditionsbenignadenomasandinflammatoryboweldisease
AT guzjolanta characteristicprofilesofdnaepigeneticmodificationsincoloncanceranditspredisposingconditionsbenignadenomasandinflammatoryboweldisease
AT linowieckakinga characteristicprofilesofdnaepigeneticmodificationsincoloncanceranditspredisposingconditionsbenignadenomasandinflammatoryboweldisease
AT bodnarmagdalena characteristicprofilesofdnaepigeneticmodificationsincoloncanceranditspredisposingconditionsbenignadenomasandinflammatoryboweldisease
AT starczakmarta characteristicprofilesofdnaepigeneticmodificationsincoloncanceranditspredisposingconditionsbenignadenomasandinflammatoryboweldisease
AT zarakowskaewelina characteristicprofilesofdnaepigeneticmodificationsincoloncanceranditspredisposingconditionsbenignadenomasandinflammatoryboweldisease
AT modrzejewskamartyna characteristicprofilesofdnaepigeneticmodificationsincoloncanceranditspredisposingconditionsbenignadenomasandinflammatoryboweldisease
AT szpilaanna characteristicprofilesofdnaepigeneticmodificationsincoloncanceranditspredisposingconditionsbenignadenomasandinflammatoryboweldisease
AT szpotanjustyna characteristicprofilesofdnaepigeneticmodificationsincoloncanceranditspredisposingconditionsbenignadenomasandinflammatoryboweldisease
AT gawronskimaciej characteristicprofilesofdnaepigeneticmodificationsincoloncanceranditspredisposingconditionsbenignadenomasandinflammatoryboweldisease
AT labejszoanna characteristicprofilesofdnaepigeneticmodificationsincoloncanceranditspredisposingconditionsbenignadenomasandinflammatoryboweldisease
AT liebertariel characteristicprofilesofdnaepigeneticmodificationsincoloncanceranditspredisposingconditionsbenignadenomasandinflammatoryboweldisease
AT banaszkiewiczzbigniew characteristicprofilesofdnaepigeneticmodificationsincoloncanceranditspredisposingconditionsbenignadenomasandinflammatoryboweldisease
AT klopockamaria characteristicprofilesofdnaepigeneticmodificationsincoloncanceranditspredisposingconditionsbenignadenomasandinflammatoryboweldisease
AT foksinskimarek characteristicprofilesofdnaepigeneticmodificationsincoloncanceranditspredisposingconditionsbenignadenomasandinflammatoryboweldisease
AT marszalekandrzej characteristicprofilesofdnaepigeneticmodificationsincoloncanceranditspredisposingconditionsbenignadenomasandinflammatoryboweldisease
AT olinskiryszard characteristicprofilesofdnaepigeneticmodificationsincoloncanceranditspredisposingconditionsbenignadenomasandinflammatoryboweldisease